Skip to main content

Grossman Adam S's Form 4 filing

Adma Biologics, Inc. (ADMA) · filed Oct 24, 2025

Accession no.
0001140361-25-039331
Filed
Oct 24, 2025
Trade date
Oct 24, 2025
Filing delay
Same day
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $336.0K. It was filed on the trade date.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Grossman Adam SCIK 0001542517Director, Officer (President and CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 24, 2025Common StockMOption exerciseAcquired+15,000$5.40+$81,0002,040,850Direct
Oct 24, 2025Common StockSSaleDisposed−15,000$16.00−$240,0002,025,850Direct
Oct 24, 2025Common StockSSaleDisposed−6,000$16.00−$96,0002,019,850Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Oct 24, 2025Common StockMOption exerciseDisposed−15,000$0.00$0750,950Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)